Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 38Genitourinary 16Gastrointestinal 13Breast 10Thoracic 8Other solid neoplasm 6Head & Neck 5CNS 5Tumor-Agnostic 4Sarcoma 3Dermatologic 3Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Thrombocytopenia 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Fallopian Tube Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 58Busulfan 47fludarabine phosphate 45Cyclosporine 34Mycophenolic Acid 31Whole-Body Irradiation 29Peripheral Blood Stem Cell Transplantation 29fludarabine 27Antilymphocyte Serum 27Tacrolimus 26Methotrexate 25Melphalan 25Filgrastim 20Radiotherapy 19Darbepoetin alfa 19Cytarabine 19Cord Blood Stem Cell Transplantation 18Epoetin Alfa 17Granulocyte Colony-Stimulating Factor 14Methylprednisolone 13thymoglobulin 10Thiotepa 9Etoposide 9Alemtuzumab 9eltrombopag 8Stem Cell Transplantation 8olaparib 7sargramostim 6hetrombopag 6Rituximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × niraparib × Classical hematology × Clear all
NCT03891576 2025-01-17

Newton

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated
83 enrolled
Classical hematologyGynecologic

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡